Miguel Fernando García‐Gil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miguel Fernando García‐Gil has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Juan Monte Serrano
Servicio de Dermatología y Venereología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
17 shared publications Mariano Ara‐Martín
Dermatology Service Lozano Blesa University Hospital Zaragoza Spain
10 shared publicationsMar García García
Department of Pathology Lozano Blesa University Clinical Hospital ZaragozaSpain
6 shared publications- Mariano Ara‐Martín
Department of Dermatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
6 shared publications Cristina Matovelle Ochoa
Department of Microbiology Lozano Blesa University Clinical Hospital Zaragoza Spain
5 shared publications- Marcial Álvarez‐Salafranca
Department of Dermatology, Hospital Universitario Miguel Servet, Zaragoza, Spain
5 shared publications
Latest Publications
- Open Access
- 11 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15879
Fully home‐based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study
Methyl aminolevulinate daylight photodynamic therapy (MAL DL‐PDT) is highly efficacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when partially performed at home. To evaluate the long‐term effectiveness, safety, and patient‐reported outcomes of MAL DL‐PDT performed completely by the patient in real life conditions. An open prospective study was conducted in Spain among patients diagnosed with at least five AK lesions on the face or the scalp. Patients received instruction and information in infographic format to perform MAL DL‐PDT at home. All had been treated with 30% urea daily for 7 days before the day of MAL DL‐PDT. Meteorological conditions on the day of the treatment and adverse effects were recorded. Patients underwent follow‐up, and a second session of home‐based MAL DL‐PDT if deemed necessary, 3, 6, and 12 months after the initial treatment session. The study population consisted of 22 patients (19 men and three women, mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response was observed in 47.7% of AK lesions at 3 months (p < 0.001) and 65.9% (n = 199) at 12 months (p < 0.001). Olsen grade II lesions showed the highest rate of response (76.07% at 12 months). The mean (SD) actinic keratosis area and severity index score decreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months (p = 0.0234). Adverse effects were mild and expected. A majority of patients were “satisfied” or “very satisfied” with the treatment instruction provided (90.9%) and the treatment outcome (72.7%). MAL DL‐PDT can be applied at home like any other topical treatment for AK. Our results indicate good long‐term effectiveness, a high level of patient satisfaction, and no significant side effects.
- 11 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15879
Open AccessFully home‐based methyl aminolevulinate daylight photodynamic therapy for actinic keratosis of the face or scalp: A real life open study
Methyl aminolevulinate daylight photodynamic therapy (MAL DL‐PDT) is highly efficacious for the treatment of nonhyperkeratotic actinic keratosis (AK), even when partially performed at home. To evaluate the long‐term effectiveness, safety, and patient‐reported outcomes of MAL DL‐PDT performed completely by the patient in real life conditions. An open prospective study was conducted in Spain among patients diagnosed with at least five AK lesions on the face or the scalp. Patients received instruction and information in infographic format to perform MAL DL‐PDT at home. All had been treated with 30% urea daily for 7 days before the day of MAL DL‐PDT. Meteorological conditions on the day of the treatment and adverse effects were recorded. Patients underwent follow‐up, and a second session of home‐based MAL DL‐PDT if deemed necessary, 3, 6, and 12 months after the initial treatment session. The study population consisted of 22 patients (19 men and three women, mean [standard deviation, SD] age, 72.05 [6.96] years). A complete response was observed in 47.7% of AK lesions at 3 months (p < 0.001) and 65.9% (n = 199) at 12 months (p < 0.001). Olsen grade II lesions showed the highest rate of response (76.07% at 12 months). The mean (SD) actinic keratosis area and severity index score decreased significantly from 4.99 (2.43) at baseline to 2.33 (1.01) at 12 months (p = 0.0234). Adverse effects were mild and expected. A majority of patients were “satisfied” or “very satisfied” with the treatment instruction provided (90.9%) and the treatment outcome (72.7%). MAL DL‐PDT can be applied at home like any other topical treatment for AK. Our results indicate good long‐term effectiveness, a high level of patient satisfaction, and no significant side effects.
- Open Access
- 1 June 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (6) , 649-651
Nuevas tecnologías aplicadas al estudio de hipopigmentaciones cutáneas
- 1 June 2022
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 113 (6) , 649-651
Open AccessNuevas tecnologías aplicadas al estudio de hipopigmentaciones cutáneas
- Open Access
- 7 December 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (2) , e15252
Papular acrodermatitis of childhood‐like eruption triggered by SARS‐CoV ‐2 vaccination: Report of two cases
Click on the article title to read more.
- 7 December 2021
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (2) , e15252
Open AccessPapular acrodermatitis of childhood‐like eruption triggered by SARS‐CoV ‐2 vaccination: Report of two cases
Click on the article title to read more.
- 30 November 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (8) , E304-E306
Obesity‐associated lymphedematous mucinosis: dermoscopic‐histopathological findings and differential diagnosis
- 30 November 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (8) , E304-E306
Obesity‐associated lymphedematous mucinosis: dermoscopic‐histopathological findings and differential diagnosis
- Open Access
- 8 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15142
No antibody response in cutaneous manifestations associated with COVID‐19: An observational study of 64 cases with microbiological and clinical characterization
Background: The microbiological diagnosis of skin lesions related to COVID‐19 is not well known. Objective: Perform a microbiological diagnosis in COVID19‐related cutaneous manifestations. Methods: A cross‐sectional study was performed with 64 patients with cutaneous manifestations associated with COVID‐19 who underwent serological and nasopharyngeal reverse transcription polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2. Results: Out of the 64 patients, 6 patients had positive RT‐PCR, with all of them developing SARS‐CoV‐2 IgG and 4 of them had positive IgM + IgA. Of the 58 patients with negative RT‐PCR, 8 cases had positive IgM + IgA and only one of them had IgG seroconversion. Therefore, the infection was demonstrated in 7 cases (10.9%) and was doubtful in 7 other cases (10.9%) who presented negative RT‐PCR and presence of IgA + IgM without subsequent seroconversion of IgG. Fifty patients (78.1%) had negative serological tests. The most frequent cutaneous pattern was pseudo‐chilblain (48.4%) followed by maculo‐papular pattern (26.6%), urticarial lesions (10.9%), vesicular eruptions (6.3%) and livedoid pattern (4.7%). The maculo‐papular pattern showed the highest positivity in RT‐PCR (3 cases; 17.6%) and serologies (4 cases; 23.5%). Skin lesions developed after the systemic symptoms in most patients (19 cases; 61.3%). Conclusions: Microbiological confirmation tests may not be an effective diagnostic technique for COVID‐related cutaneous manifestations or that attributed lesions are not related to COVID‐19. Confounding factors such as adverse drug reaction, serological cross‐reactions with other viruses, the low production of antibodies in asymptomatic or mild forms of COVID‐19 or its rapid disappearance, increase diagnostic uncertainty.
- 8 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15142
Open AccessNo antibody response in cutaneous manifestations associated with COVID‐19: An observational study of 64 cases with microbiological and clinical characterization
Background: The microbiological diagnosis of skin lesions related to COVID‐19 is not well known. Objective: Perform a microbiological diagnosis in COVID19‐related cutaneous manifestations. Methods: A cross‐sectional study was performed with 64 patients with cutaneous manifestations associated with COVID‐19 who underwent serological and nasopharyngeal reverse transcription polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2. Results: Out of the 64 patients, 6 patients had positive RT‐PCR, with all of them developing SARS‐CoV‐2 IgG and 4 of them had positive IgM + IgA. Of the 58 patients with negative RT‐PCR, 8 cases had positive IgM + IgA and only one of them had IgG seroconversion. Therefore, the infection was demonstrated in 7 cases (10.9%) and was doubtful in 7 other cases (10.9%) who presented negative RT‐PCR and presence of IgA + IgM without subsequent seroconversion of IgG. Fifty patients (78.1%) had negative serological tests. The most frequent cutaneous pattern was pseudo‐chilblain (48.4%) followed by maculo‐papular pattern (26.6%), urticarial lesions (10.9%), vesicular eruptions (6.3%) and livedoid pattern (4.7%). The maculo‐papular pattern showed the highest positivity in RT‐PCR (3 cases; 17.6%) and serologies (4 cases; 23.5%). Skin lesions developed after the systemic symptoms in most patients (19 cases; 61.3%). Conclusions: Microbiological confirmation tests may not be an effective diagnostic technique for COVID‐related cutaneous manifestations or that attributed lesions are not related to COVID‐19. Confounding factors such as adverse drug reaction, serological cross‐reactions with other viruses, the low production of antibodies in asymptomatic or mild forms of COVID‐19 or its rapid disappearance, increase diagnostic uncertainty.
- Open Access
- 1 June 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (6) , 553-555
RF- Immunotherapy in Merkel Cell Carcinoma
- 1 June 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (6) , 553-555
Open AccessRF- Immunotherapy in Merkel Cell Carcinoma
- Open Access
- 1 June 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (6) , 553-555
FR -Inmunoterapia en el carcinoma de células de Merkel
- 1 June 2021
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 112 (6) , 553-555
Open AccessFR -Inmunoterapia en el carcinoma de células de Merkel
- 17 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3)
Granuloma annulare triggered by SARS‐CoV ‐2 infection: Immunohistochemical staining
- 17 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3)
Granuloma annulare triggered by SARS‐CoV ‐2 infection: Immunohistochemical staining
- Open Access
- 4 February 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (5) , E318-E321
Absence of SARS‐CoV‐2 RNA detection in tissue samples of COVID‐19‐related cutaneous lesions analyzed by real‐time RT‐PCR
Despite the increasing knowledge of COVID‐19‐related skin lesions, few studies have attempted to demonstrate the presence of the virus in skin lesions by real‐time reverse transcriptase polymerase chain reaction (RT‐PCR).1,2 The objective of this research was to determine through RT‐PCR whether SARS‐CoV‐2 was present in skin biopsies of patients with cutaneous manifestations related to COVID‐19.
- 4 February 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (5) , E318-E321
Open AccessAbsence of SARS‐CoV‐2 RNA detection in tissue samples of COVID‐19‐related cutaneous lesions analyzed by real‐time RT‐PCR
Despite the increasing knowledge of COVID‐19‐related skin lesions, few studies have attempted to demonstrate the presence of the virus in skin lesions by real‐time reverse transcriptase polymerase chain reaction (RT‐PCR).1,2 The objective of this research was to determine through RT‐PCR whether SARS‐CoV‐2 was present in skin biopsies of patients with cutaneous manifestations related to COVID‐19.
- 1 February 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (6) , E244-E246
Reply to: post‐emesis periorbital purpura in hyperemesis gravidarum
- 1 February 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (6) , E244-E246
Reply to: post‐emesis periorbital purpura in hyperemesis gravidarum